The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas.

ABSTRACT:

Background

Results from previous trials suggest that daptomycin may result in faster clinical improvement than penicillinase-resistant penicillins or vancomycin for patients with complicated skin and skin structure infections.

Objective

The objective was to evaluate whether daptomycin treatment of cellulitis or erysipelas would result in faster resolution compared with vancomycin.

Design

The study was a prospective, evaluator-blinded, multi-centre trial. Patients were randomised to receive daptomycin 4 mg/kg once daily or vancomycin according to standard of care for 7-14 days.

Patients

Adults diagnosed with cellulitis or erysipelas requiring hospitalisation and intravenous antibiotic therapy were eligible for enrolment.

Results

The clinical success rates

SUBMITTER: Pertel PE 

PROVIDER: S-EPMC2705813 | biostudies-literature | 2009 Mar

REPOSITORIES: biostudies-literature